Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

Data Being Presented Today at 44th Annual Meeting of EASL

Management to Discuss Study Results and Program Status During Q1 Financial Results Call at 5 P.M. EDT Today

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that ANA598, the Company's investigational non-nucleoside polymerase inhibitor, demonstrated potent antiviral activity at all dose levels and was well tolerated in a Phase Ib study in which patients chronically infected with the Hepatitis C virus (HCV) were treated for three days. The results from the recently completed study are being presented today during the late-breaker poster session at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark.

In the study, ANA598 treatment resulted in rapid and sustained reductions in HCV RNA with median reductions at end of treatment (Day 4) exceeding 2 log10 (>99%) at all dose levels. At 200 mg bid (twice-daily), the median viral load reduction was 2.4 log10 (range of 0.4 to 3.4); at 400 mg bid, 2.3 log10 (range of 1.6 to 3.5); and at 800 mg bid, 2.9 log10 (range of 2.2 to 3.4). Genotype 1a patients demonstrated median reductions of 1.4 log10, 1.8 log10, and 2.5 log10 at 200, 400 and 800 mg bid, respectively. In 10 of the 12 genotype 1a patients who received ANA598, viral load was still declining at the end of the three days of treatment. Genotype 1b patients demonstrated median reductions of 2.6 log10, 2.5 log10, and 3.2 log10, at 200, 400 and 800 mg bid, respectively. No patient showed evidence of viral rebound while on ANA598. ANA598 was well-tolerated in this short term study and there were no serious adverse events.

Steve Worland, Ph.D., Anadys' President and CEO, commented that "The potent antiviral activity demonstra
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , Mar. 02, 2015 Research and Markets ... addition of the "Lopinavir - Comprehensive patent ... Imagine having your own team of ... button. Used by the world,s leading ... years, these searches are the benchmark in comprehensive, ...
(Date:3/2/2015)... , March 2, 2015 Shire plc ... the company has submitted a New Drug Application (NDA) with ... compound lifitegrast for the treatment of signs and symptoms of ... to be the first treatment indicated to address both the ... condition which affects millions of people," said Philip J. ...
(Date:3/2/2015)... , March 2, 2015 The Economist Events, ... last week on 26 February was host to some ... a number of topical issues facing the sector. This year,s theme, ... E ra , , observed the challenges the industry ... Panel speakers offered contrasting and thought-provoking commentary on how ...
Breaking Medicine Technology:Global Comprehensive Lopinavir Patent Search Online Portal 2015 2Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 2Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 3Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 421 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 221 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 321 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 421 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 521 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events' Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry 6
... WLP ) announced today that its subsidiary, ... for Medicare & Medicaid Services (CMS) to continue administering ... for Jurisdiction B, which includes the states of Illinois, ... National Government Services was originally awarded the Jurisdiction ...
... 21 A new study released on September 20, ... details a breakthrough innovation in post-op treatment for ... Plastic and Reconstructive Surgeon Dr. Andrew Jacono details how ... facelifts, and proves to decrease bruising by 35 percent, ...
Cached Medicine Technology:WellPoint Subsidiary Wins Durable Medical Equipment Medicare Administrative Contract Valued at $86.7 Million 2Facelift Healing Innovation: New Study Shows Hyperbaric Oxygen Therapy Decreases Bruising in Facelifts Patients by 35% 2
(Date:3/2/2015)... March 02, 2015 Doctors in Novara, ... a better predictor of outcomes for people with mesothelioma ... details of the new study on the Surviving ... the University of Eastern Piedmont followed the cases of ... treatment for excess lung fluid. , “Persistent lung ...
(Date:3/2/2015)... 02, 2015 Burns Engineering's Lab-to-Lab ... for Secondary Standard Platinum Resistance Thermometers (SSPRTs) and ... days or less . . . guaranteed. ... Accredited (Lab Code 200706-0), ISO 9001 and 17025 ... range is -196°C to 500°C, both ITS-90 and ...
(Date:3/2/2015)... The minimally invasive surgical instruments market is expected ... reach $14,133.0 million by 2019 from $10,526.2 million ... of minimally invasive surgeries over traditional open surgeries, ... and increasing number of surgical procedures among the ... surgical instruments market. , For More Details @ ...
(Date:3/2/2015)... Four Seasons Resort Maui at Wailea, the ... this year, having officially opened its doors on March 2, ... honoring over 70 employees who started on Day 1 and ... approximately 400 original employees. The celebration will be a ... , This Four Seasons flagship resort, the first resort ...
(Date:3/2/2015)... Bangladesh (PRWEB) March 02, 2015 The ... of fire safety expert Mark Chubb to serve as ... fire safety operations and training in Bangladesh and guide ... source. , “Mark will ensure that the Alliance ... fire safety programs for Bangladesh garment workers,” said Alliance ...
Breaking Medicine News(10 mins):Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2
... flu antibodies in migrant birds in five Siberian regions, a ... ,"Out of over 4,000 samples taken in the area ... contain genetic material of the A-H5 virus and antibodies in ... said the presence of antibodies meant that either the birds ...
... two studies indicate that elevated nonfasting triglyceride levels ... heart attack , with one study finding that ... this association. ,Triglyceride levels are usually ... certain types of lipoprotein particles (remnant lipoproteins), a ...
... they have been discharged from hospital for an asthma attack ... Review has found. Giving the steroids also reduces their use ... ,This updated finding was drawn after reviewing data in ... and 16% of people who are discharged from hospital after ...
... and exercise is a more effective way of losing weight ... gain weight during pregnancy and many gradually lose it afterwards, ... weight. This retained body weight may be one factor that ... find ways of returning to, and maintaining, pre-pregnant weights, and ...
... Cochrane Systematic Review has concluded,Spraying salty water (saline) into ... and congestion that accompany long-term infections of the ... people experience persistent infection of the nasal passages (chronic ... spraying saline into the nose to relieve symptoms, and ...
... heart beats and have a tendency to form blood clots ... clots can then travel to the brain, block vessels and ... risk of this occurring is to give drugs that limit ... are anticoagulants that inhibit the clotting process (e.g. warfarin), and ...
Cached Medicine News:Health News:High Nonfasting Triglyceride Levels Linked With Cardiovascular Risks 2Health News:Anticoagulants is Better for Atrial Fibrillation 2
Inquire...
... false signals and contamination caused by ... Barrier Tips offer performance and economy ... (PCR(a)), radioactive isotopes, tissue culture fluids, ... , ,Promega Barrier Tips are made ...
... Filters are ideal for PCR ... for any work where aerosol ... designed for pipetting DNA/RNA solutions, ... other. For applications requiring absolute ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
Medicine Products: